Entering text into the input field will update the search result below

Novavax +20% after scoring $1.6B in funding from Operation Warp Speed

Jul. 07, 2020 6:21 AM ETNovavax, Inc. (NVAX) StockNVAXBy: Yoel Minkoff, SA News Editor117 Comments
  • The OWS award funds large-scale manufacturing of NVX-CoV2373, Novavax's (NASDAQ:NVAX) COVID-19 vaccine candidate including production of 100M doses starting in late 2020.
  • That includes a pivotal Phase 3 clinical trial with up to 30,000 subjects beginning in the fall of 2020. A Phase 1/2 clinical trial of NVX-CoV2373 in 130 healthy participants 18 to 59 years of age began in Australia in May.
  • Preliminary immunogenicity and safety results are expected at the end of July, and the Phase 2 portion to assess immunity, safety, and COVID-19 disease reduction is expected to begin thereafter.
  • NVAX +19.6% premarket

Recommended For You

About NVAX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVAX--
Novavax, Inc.